Earnings Call · Q4 FY2025·2026-02-12

Q4 25EPS -11.50%·Rev n/aQ3 25EPS -17.54%·Rev n/aQ2 25EPS -4.09%·Rev n/aQ1 25EPS +10.36%·Rev n/a⚠ consensus missing

Karyopharm Therapeutics Inc. KPTI

Brendan Strong — Investor Relations or similar role

Reshma Rangwala — Chief Medical Officer

Lori Macomber — Chief Financial Officer

+21.3%1d on move date+22.8% vs SPY3d+27.5%5d+31.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KPTI calls or request research access.

More KPTI calls Browse calls Request research access